Incidence and Clinical Outcomes of Clostridium difficile Infection after Treatment with Tuberculosis Medication
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Yu Mi | - |
dc.contributor.author | Huh, Kyu Chan | - |
dc.contributor.author | Yoon, Soon Man | - |
dc.contributor.author | Jang, Byung Ik | - |
dc.contributor.author | Shin, Jeong Eun | - |
dc.contributor.author | Koo, Hoon Sup | - |
dc.contributor.author | Jung, Yunho | - |
dc.contributor.author | Kim, Sae Hee | - |
dc.contributor.author | Moon, Hee Seok | - |
dc.contributor.author | Lee, Seung Woo | - |
dc.date.accessioned | 2021-08-11T17:46:33Z | - |
dc.date.available | 2021-08-11T17:46:33Z | - |
dc.date.issued | 2016-03 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.issn | 2005-1212 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/9333 | - |
dc.description.abstract | Background/Aims: To determine the incidence and clinical characteristics of tuberculosis (TB) medication-associated Clostridium difficile infection. Methods: This multicenter study included patients from eight tertiary hospitals enrolled from 2008 to 2013. A retrospective analysis was conducted to identify the clinical features of C. difficile infection in patients who received TB medication. Results: C. difficile infection developed in 54 of the 19,080 patients prescribed TB medication, representing a total incidence of infection of 2.83 cases per 1,000 adults. Fifty-one of the 54 patients (94.4%) were treated with rifampin. The patients were usually treated with oral metronidazole, which produced improvement in 47 of the 54 patients (87%). Twenty-three patients clinically improved with continuous rifampin therapy for C. difficile infection. There were no significant differences in improvement between patients treated continuously (n=21) and patients in whom treatment was discontinued (n=26). Conclusions: The incidence of C. difficile infection after TB medication was not low considering the relatively low TB medication dosage compared to other antibiotics. It may not be always necessary to discontinue TB medication. Instead, decisions concerning discontinuation of TB medication should be based on TB status. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 거트앤리버 발행위원회 | - |
dc.title | Incidence and Clinical Outcomes of Clostridium difficile Infection after Treatment with Tuberculosis Medication | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5009/gnl14435 | - |
dc.identifier.scopusid | 2-s2.0-84960488319 | - |
dc.identifier.wosid | 000371851900013 | - |
dc.identifier.bibliographicCitation | Gut and Liver, v.10, no.2, pp 250 - 254 | - |
dc.citation.title | Gut and Liver | - |
dc.citation.volume | 10 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 250 | - |
dc.citation.endPage | 254 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002089662 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | PSEUDOMEMBRANOUS COLITIS | - |
dc.subject.keywordPlus | RIFAMPICIN | - |
dc.subject.keywordAuthor | Enterocolitis, pseudomembranous | - |
dc.subject.keywordAuthor | Clostridium difficile | - |
dc.subject.keywordAuthor | Tuberculosis | - |
dc.subject.keywordAuthor | Rifampin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.